PTIX — Protagenic Therapeutics, Inc.

Summary of PTIX Q4 2023 Earnings Call

1. Key Financial Results and Metrics

• Q4 2023 Financials:

  • R&D expenses: $1.0 million, a 301% increase from $258,000 in Q4 2022, primarily due to the initiation of clinical trials for PT00114.
  • General and Administrative (G&A) expenses: $201,000, down 50% from the previous year, attributed to minimal stock-based compensation.
  • Net loss: $1.2 million, compared to a net loss of $656,000 in Q4 2022.

• Full Year 2023 Financials:

  • Total R&D expenses: $3.3 million, up 109% from $1.6 million in 2022.
  • Full-year net loss: $4.5 million, a 27% increase from 2022, driven by higher R&D spending.
  • Cash and cash equivalents at year-end: $4.1 million, down from $8.0 million at the end of 2022, but deemed sufficient to fund the Phase 1 clinical trial.

2. Strategic Updates and Business Highlights

• PTIX initiated its first clinical trial for its lead product, PT00114, targeting conditions such as depression, anxiety, PTSD, and addiction.
• The drug candidate is based on Teneurin C-terminal associated peptide (TCAP) and is designed to work through a novel mechanism, potentially offering fewer side effects than existing treatments.
• The company has engaged with experts, including Dr. Maurizio Fava from Harvard, to guide its clinical development.
• Preclinical studies have shown PT00114's potential to modulate brain responses to stress, with a focus on its effects in the amygdala.

3. Forward Guidance and Outlook

• PTIX plans to complete enrollment for the single ascending dose (SAD) study by the end of April 2024, with data readout expected by mid-May.
• The multiple ascending dose (MAD) study will commence immediately after the SAD completion, with results anticipated in early Q3 2024.
• The company is finalizing its Phase 2 protocol and expects to submit it to regulatory agencies soon, leveraging the safety profile observed in early trials.

4. Bad News, Challenges, or Points of Concern

• The increase in net loss and cash burn raises concerns about the company’s financial sustainability without additional funding or revenue generation.
• The decline in cash reserves from $8.0 million to $4.1 million may necessitate future financing efforts, which could dilute existing shareholders.
• The company faces the inherent risks associated with clinical trials, including potential delays, regulatory hurdles, and the need for successful outcomes to advance to later stages of development.

5. Notable Q&A Insights

• The timeline for SAD and MAD studies was clarified, with SAD data expected by mid-May and MAD results in early Q3 2024.
• The company is collecting biomarker data, including cortisol levels, which will be reported alongside trial results to assess the drug's effects on stress response.
• The Phase 2 study will be designed as a "basket trial" to evaluate PT00114 across various neuropsychiatric disorders, enhancing regulatory acceptance.

Overall, PTIX is positioned at a critical juncture with the advancement of PT00114 into clinical trials, but it must navigate financial and operational challenges as it seeks to establish its product in the competitive mental health treatment landscape.